A Phase 2 interventional study of CNTO 1959 (5 mg) and CNTO 1959 (15 mg) in Psoriasis, sponsored by Janssen Inc.. Completed at 40 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-08-02.
Sponsored by Janssen Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 2, and was the 2nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 26th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2011, is one of 12 in phase 2, and was the 30th registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
This is a multicenter, dose-ranging study of CNTO 1959 in patients with moderate to severe plaque psoriasis. Patients who satisfy all inclusion and exclusion criteria will be assigned by chance to one of 7 treatment groups: a placebo group (a placebo is a treatment identical in appearance to CNTO 1959 but does not contain active drug), 1 of 5 dose groups for CNTO 1959, or adalimumab. Patients assigned to adalimumab will be dosed according to the labeled dosing for psoriasis. At Week 16, patients initially assigned to placebo will begin receiving CNTO 1959. Patients initially assigned to CNTO 1959 will continue to receive the same assigned dose level of study agent from Week 16 through Week 40. Patients receiving adalimumab will continue the labeled dosing regimen. All patients will be reassessed for clinical response every 4 weeks from Week 4 through Week 40. Patients will continue dosing through Week 40, with a subsequent efficacy and safety follow-up visit at Week 52. Patient safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Drug: CNTO 1959 (5 mg)
CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
Drug: CNTO 1959 (15 mg)
CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Drug: CNTO 1959 (50 mg)
CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
Drug: CNTO 1959 (100 mg)
CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Drug: CNTO 1959 (200 mg)
Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
Drug: Adalimumab
Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
Drug: CNTO 1959 (100 mg) · Drug: Placebo
Subcutaneous (SC) injections
SC injections
SC injections
SC injections
SC injections
SC injections
SC injections
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Time frame: Week 16
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
Time frame: Week 16
Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Time frame: Week 16
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Time frame: Week 40
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
Time frame: Baseline and Week 16
| Milestone | Placebo (CP) | CNTO1959 5 mg (CP) | CNTO1959 15 mg (CP) | CNTO1959 50 mg (CP) | CNTO1959 100 mg (CP) | CNTO1959 200 mg (CP) | Adalimumab (CP) | Placebo -> 100 mg CNTO1959 (After CP) | CNTO1959 5 mg (After CP) | CNTO1959 15 mg (After CP) | CNTO1959 50 mg (After CP) | CNTO1959 100 mg (After CP) | CNTO1959 200 mg (After CP) | Adalimumab (After CP) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 42 | 41 | 41 | 42 | 42 | 42 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 42 | 41 | 41 | 42 | 42 | 41 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 39 | 38 | 41 | 39 | 40 | 38 | 39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 0 | 3 | 2 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 1 | 1 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (CP) | CNTO1959 5 mg (CP) | CNTO1959 15 mg (CP) | CNTO1959 50 mg (CP) | CNTO1959 100 mg (CP) | CNTO1959 200 mg (CP) | Adalimumab (CP) | Placebo -> 100 mg CNTO1959 (After CP) | CNTO1959 5 mg (After CP) | CNTO1959 15 mg (After CP) | CNTO1959 50 mg (After CP) | CNTO1959 100 mg (After CP) | CNTO1959 200 mg (After CP) | Adalimumab (After CP) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 | 38 | 41 | 39 | 40 | 38 | 39 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 29 | 37 | 37 | 39 | 35 | 32 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 4 | 2 | 1 | 3 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 1 | 0 |
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
| percentage of participants | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16 | 7.1 | 34.1 | 61.0 | 78.6 | 85.7 | 83.3 | 58.1 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
| percentage of participants | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 | 4.8 | 43.9 | 75.6 | 81.0 | 78.6 | 81.0 | 69.8 |
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
| percentage of participants | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab |
|---|---|---|---|---|---|---|
| Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16 | 34.1 | 61.0 | 78.6 | 85.7 | 83.3 | 58.1 |
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
| percentage of participants | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab |
|---|---|---|---|---|---|---|
| Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40 | 35.3 | 59.5 | 71.1 | 76.9 | 81.1 | 48.6 |
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.
| units on a scale | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16 | -2.3 ± 6.80 | -6.2 ± 5.24 | -10.3 ± 5.49 | -11.1 ± 7.38 | -10.8 ± 7.34 | -11.4 ± 6.83 | -10.1 ± 9.00 |
Collected over Baseline (Week 0) up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (CP) | — | 1/42 (2.4%) | 13/42 (31%) |
| CNTO1959 5 mg (CP) | — | 0/41 (0%) | 15/41 (36.6%) |
| CNTO1959 15 mg (CP) | — | 0/41 (0%) | 10/41 (24.4%) |
| CNTO1959 50 mg (CP) | — | 3/42 (7.1%) | 10/42 (23.8%) |
| CNTO1959 100 mg (CP) | — | 0/42 (0%) | 7/42 (16.7%) |
| CNTO1959 200 mg (CP) | — | 0/41 (0%) | 8/41 (19.5%) |
| Adalimumab (CP) | — | 1/43 (2.3%) | 10/43 (23.3%) |
| Placebo -> 100 mg CNTO1959 (After CP) | — | 0/39 (0%) | 16/39 (41%) |
| CNTO1959 5 mg (After CP) | — | 2/38 (5.3%) | 12/38 (31.6%) |
| CNTO1959 15 mg (After CP) | — | 0/41 (0%) | 4/41 (9.8%) |
| CNTO1959 50 mg (After CP) | — | 0/39 (0%) | 11/39 (28.2%) |
| CNTO1959 100 mg (After CP) | — | 2/40 (5%) | 16/40 (40%) |
| CNTO1959 200 mg (After CP) | — | 0/38 (0%) | 12/38 (31.6%) |
| Adalimumab (After CP) | — | 1/38 (2.6%) | 13/38 (34.2%) |
| Event | Placebo (CP) | CNTO1959 5 mg (CP) | CNTO1959 15 mg (CP) | CNTO1959 50 mg (CP) | CNTO1959 100 mg (CP) | CNTO1959 200 mg (CP) | Adalimumab (CP) | Placebo -> 100 mg CNTO1959 (After CP) | CNTO1959 5 mg (After CP) | CNTO1959 15 mg (After CP) | CNTO1959 50 mg (After CP) | CNTO1959 100 mg (After CP) | CNTO1959 200 mg (After CP) | Adalimumab (After CP) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 1/38 | 0/41 | 0/39 | 1/40 | 0/38 | 0/38 |
| Oesophagitis HaemorrhagicGastrointestinal disorders | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 1/38 |
| PneumoniaInfections and infestations | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 1/38 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 1/38 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 1/38 | 0/41 | 0/39 | 0/40 | 0/38 | 0/38 |
| Cerebrovascular AccidentNervous system disorders | 0/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 1/40 | 0/38 | 0/38 |
| Umbilical HerniaGastrointestinal disorders | 0/42 | 0/41 | 0/41 | 1/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 0/38 |
| AppendicitisInfections and infestations | 0/42 | 0/41 | 0/41 | 1/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 0/38 |
| Lung AbscessInfections and infestations | 0/42 | 0/41 | 0/41 | 1/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 0/38 |
| Uterine ProlapseReproductive system and breast disorders | 1/42 | 0/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 0/38 |
| Event | Placebo (CP) | CNTO1959 5 mg (CP) | CNTO1959 15 mg (CP) | CNTO1959 50 mg (CP) | CNTO1959 100 mg (CP) | CNTO1959 200 mg (CP) | Adalimumab (CP) | Placebo -> 100 mg CNTO1959 (After CP) | CNTO1959 5 mg (After CP) | CNTO1959 15 mg (After CP) | CNTO1959 50 mg (After CP) | CNTO1959 100 mg (After CP) | CNTO1959 200 mg (After CP) | Adalimumab (After CP) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/42 | 6/41 | 4/41 | 1/42 | 1/42 | 2/41 | 2/43 | 4/39 | 6/38 | 1/41 | 7/39 | 4/40 | 5/38 | 6/38 |
| Injection Site ErythemaGeneral disorders | 1/42 | 0/41 | 0/41 | 0/42 | 1/42 | 1/41 | 5/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 2/38 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/42 | 3/41 | 0/41 | 1/42 | 0/42 | 3/41 | 2/43 | 4/39 | 4/38 | 1/41 | 0/39 | 3/40 | 2/38 | 3/38 |
| HeadacheNervous system disorders | 1/42 | 3/41 | 4/41 | 1/42 | 2/42 | 0/41 | 0/43 | 1/39 | 1/38 | 0/41 | 1/39 | 2/40 | 1/38 | 0/38 |
| PsoriasisSkin and subcutaneous tissue disorders | 4/42 | 1/41 | 0/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 1/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/42 | 1/41 | 0/41 | 1/42 | 1/42 | 1/41 | 2/43 | 3/39 | 2/38 | 0/41 | 0/39 | 1/40 | 1/38 | 1/38 |
| Back PainMusculoskeletal and connective tissue disorders | 0/42 | 3/41 | 1/41 | 0/42 | 2/42 | 0/41 | 0/43 | 0/39 | 0/38 | 1/41 | 1/39 | 2/40 | 1/38 | 0/38 |
| FatigueGeneral disorders | 3/42 | 1/41 | 1/41 | 2/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 1/38 | 0/38 |
| HypertensionVascular disorders | 1/42 | 1/41 | 0/41 | 3/42 | 1/42 | 1/41 | 0/43 | 1/39 | 0/38 | 0/41 | 1/39 | 2/40 | 1/38 | 1/38 |
| Influenza Like IllnessGeneral disorders | 0/42 | 0/41 | 1/41 | 0/42 | 0/42 | 0/41 | 0/43 | 0/39 | 0/38 | 0/41 | 0/39 | 0/40 | 0/38 | 2/38 |
Population analyzed included all participants who were randomized.
| Age, Categorical(Participants) | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Between 18 and 65 years | 41 | 39 | 39 | 41 | 36 | 40 | 35 | 271 |
| >=65 years | 1 | 1 | 2 | 1 | 6 | 2 | 8 | 21 |
| Age, Continuous(years) | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 45 ± 11.97 | 45.2 ± 13.92 | 43.8 ± 13.5 | 42.6 ± 12.14 | 45.3 ± 13.72 | 45.1 ± 10.96 | 47.5 ± 14.91 | 44.9 ± 13.02 |
| Sex: Female, Male(Participants) | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 14 | 13 | 13 | 12 | 10 | 11 | 13 | 86 |
| Male | 28 | 28 | 28 | 30 | 32 | 31 | 30 | 207 |
| Region of Enrollment(participants) | Placebo | CNTO1959 5 mg | CNTO1959 15 mg | CNTO1959 50 mg | CNTO1959 100 mg | CNTO1959 200 mg | Adalimumab | Total |
|---|---|---|---|---|---|---|---|---|
| Germany | 2 | 2 | 4 | 5 | 4 | 3 | 3 | 23 |
| Belgium | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 5 |
| Poland | 7 | 8 | 7 | 10 | 7 | 8 | 8 | 55 |
| Canada | 13 | 11 | 11 | 11 | 12 | 14 | 11 | 83 |
| United States | 18 | 19 | 19 | 16 | 18 | 16 | 21 | 127 |
Ran from Nov 2011 to primary completion in Nov 2012, 12 months.
Results were first posted in Aug 2017, 4 years 8 months after primary completion. A results delay was requested in Oct 2013.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 12 months is close to that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab